The partners will incorporate BostonGene's Tumor Portrait tests into SCRI's Phase I clinical trials to explore the use of HLA typing for pre-screening patients.
Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.